MedTech giant Boston Scientific disclosed a cyber incident causing IT outages and disruption across its global operations.
Boston Scientific revealed that a cyber incident triggered IT outages disrupting its worldwide operations. The medical device manufacturer has not yet confirmed whether data was accessed or whether ransomware is involved. Details on scope and impact remain limited as the investigation continues.
ShinyHunters claims theft of 284 million patient records from McKesson via vishing, Okta takeover, and Salesforce/Snowflake access, demanding $55,236,150.
McKesson disclosed in an SEC filing a cybersecurity incident detected August 25, 2026, involving unauthorized access to third-party applications and data exfiltration affecting a subset of customers in its Oncology & Multispecialty and Medical-Surgical business units. ShinyHunters told BleepingComputer it entered through vishing calls to employees, used stolen credentials to take over Okta single sign-on accounts, and extracted about a terabyte of data from Salesforce and Snowflake environments over four days. The group claims 284 million database rows including names, addresses, Social Security numbers, Medicaid details, medical record numbers, and medication data, and demanded $55,236,150 with a 72-hour deadline; none of these claims have been independently verified.
Boston Scientific disclosed a cyberattack that caused a network outage, disrupting global operations including order processing and shipping.
The medical device maker detected the incident on August 25, activated incident response protocols with third-party cybersecurity experts, and told the SEC that access to systems supporting operations, including order processing and shipping, was disrupted. Boston Scientific employs about 59,000 people across 127 countries and posted more than $20 billion in net sales in 2025; it has not determined whether the incident is material and no group has claimed responsibility. The company joins a recent run of medtech attacks including Stryker, iRhythm, Novo Nordisk and Xsolis.